Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges

Monika Toporkiewicz, Justyna Meissner, Lucyna Matusewicz, Aleksander Czogalla, Aleksander F SikorskiLaboratory of Cytobiochemistry, Faculty of Biotechnology, University of Wrocław, Wrocław, PolandAbstract: There are many problems directly correlated with the systemic administration of drugs and how...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Toporkiewicz M, Meissner J, Matusewicz L, Czogalla A, Sikorski AF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/572fe198e89a4e1bafd3688e19e61a5b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:572fe198e89a4e1bafd3688e19e61a5b
record_format	dspace
spelling	oai:doaj.org-article:572fe198e89a4e1bafd3688e19e61a5b2021-12-02T02:32:07ZToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges1178-2013https://doaj.org/article/572fe198e89a4e1bafd3688e19e61a5b2015-02-01T00:00:00Zhttp://www.dovepress.com/toward-a-magic-or-imaginary-bullet-ligands-for-drug-targeting-to-cance-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Monika Toporkiewicz, Justyna Meissner, Lucyna Matusewicz, Aleksander Czogalla, Aleksander F SikorskiLaboratory of Cytobiochemistry, Faculty of Biotechnology, University of Wrocław, Wrocław, PolandAbstract: There are many problems directly correlated with the systemic administration of drugs and how they reach their target site. Targeting promises to be a hopeful strategy as an improved means of drug delivery, with reduced toxicity and minimal adverse side effects. Targeting exploits the high affinity of cell-surface-targeted ligands, either directly or as carriers for a drug, for specific retention and uptake by the targeted diseased cells. One of the most important parameters which should be taken into consideration in the selection of an appropriate ligand for targeting is the binding affinity (KD). In this review we focus on the importance of binding affinities of monoclonal antibodies, antibody derivatives, peptides, aptamers, DARPins, and small targeting molecules in the process of selection of the most suitable ligand for targeting of nanoparticles. In order to provide a critical comparison between these various options, we have also assessed each technology format across a range of parameters such as molecular size, immunogenicity, costs of production, clinical profiles, and examples of the level of selectivity and toxicity of each. Wherever possible, we have also assessed how incorporating such a targeted approach compares with, or is superior to, original treatments.Keywords: targeting, drug delivery, tumor, monoclonal antibody, EGFR, cancerToporkiewicz MMeissner JMatusewicz LCzogalla ASikorski AF,Dove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2015, Iss default, Pp 1399-1414 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Toporkiewicz M Meissner J Matusewicz L Czogalla A Sikorski AF, Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges
description	Monika Toporkiewicz, Justyna Meissner, Lucyna Matusewicz, Aleksander Czogalla, Aleksander F SikorskiLaboratory of Cytobiochemistry, Faculty of Biotechnology, University of Wrocław, Wrocław, PolandAbstract: There are many problems directly correlated with the systemic administration of drugs and how they reach their target site. Targeting promises to be a hopeful strategy as an improved means of drug delivery, with reduced toxicity and minimal adverse side effects. Targeting exploits the high affinity of cell-surface-targeted ligands, either directly or as carriers for a drug, for specific retention and uptake by the targeted diseased cells. One of the most important parameters which should be taken into consideration in the selection of an appropriate ligand for targeting is the binding affinity (KD). In this review we focus on the importance of binding affinities of monoclonal antibodies, antibody derivatives, peptides, aptamers, DARPins, and small targeting molecules in the process of selection of the most suitable ligand for targeting of nanoparticles. In order to provide a critical comparison between these various options, we have also assessed each technology format across a range of parameters such as molecular size, immunogenicity, costs of production, clinical profiles, and examples of the level of selectivity and toxicity of each. Wherever possible, we have also assessed how incorporating such a targeted approach compares with, or is superior to, original treatments.Keywords: targeting, drug delivery, tumor, monoclonal antibody, EGFR, cancer
format	article
author	Toporkiewicz M Meissner J Matusewicz L Czogalla A Sikorski AF,
author_facet	Toporkiewicz M Meissner J Matusewicz L Czogalla A Sikorski AF,
author_sort	Toporkiewicz M
title	Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges
title_short	Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges
title_full	Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges
title_fullStr	Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges
title_full_unstemmed	Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges
title_sort	toward a magic or imaginary bullet? ligands for drug targeting to cancer cells: principles, hopes, and challenges
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/572fe198e89a4e1bafd3688e19e61a5b
work_keys_str_mv	AT toporkiewiczm towardamagicorimaginarybulletligandsfordrugtargetingtocancercellsprincipleshopesandchallenges AT meissnerj towardamagicorimaginarybulletligandsfordrugtargetingtocancercellsprincipleshopesandchallenges AT matusewiczl towardamagicorimaginarybulletligandsfordrugtargetingtocancercellsprincipleshopesandchallenges AT czogallaa towardamagicorimaginarybulletligandsfordrugtargetingtocancercellsprincipleshopesandchallenges AT sikorskiaf towardamagicorimaginarybulletligandsfordrugtargetingtocancercellsprincipleshopesandchallenges
_version_	1718402409377562624

Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges

Ejemplares similares